Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.

Science signaling

Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR.
PMID: 34429382
Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606.

Chimeric antigen receptor (CAR)-modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T...

Cite
Salter AI, Rajan A, Kennedy JJ, et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021;14(697)doi: 10.1126/scisignal.abe2606.
Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., & Riddell, S. R. (2021). Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Science signaling, 14(697), . https://doi.org/10.1126/scisignal.abe2606
Salter, Alexander I, et al. "Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function." Science signaling vol. 14,697 (2021). doi: https://doi.org/10.1126/scisignal.abe2606
Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606. PMID: 34429382; PMCID: PMC8613804.
Copy Download .nbib Format: NLM
Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling.

Cell reports methods

Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG.
PMID: 34671754
Cell Rep Methods. 2021 Jul 26;1(3). doi: 10.1016/j.crmeth.2021.100015. Epub 2021 Jun 14.

SUMMARY: A primary goal of the US National Cancer Institute's Ras initiative at the Frederick National Laboratory for Cancer Research is to develop methods to quantify RAS signaling to facilitate development of novel cancer therapeutics. We use targeted proteomics...

Cite
Whiteaker JR, Sharma K, Hoffman MA, et al. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Cell Rep Methods. 2021;1(3)doi: 10.1016/j.crmeth.2021.100015.
Whiteaker, J. R., Sharma, K., Hoffman, M. A., Kuhn, E., Zhao, L., Cocco, A. R., Schoenherr, R. M., Kennedy, J. J., Voytovich, U., Lin, C., Fang, B., Bowers, K., Whiteley, G., Colantonio, S., Bocik, W., Roberts, R., Hiltke, T., Boja, E., Rodriguez, H., McCormick, F., Holderfield, M., Carr, S. A., Koomen, J. M., & Paulovich, A. G. (2021). Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Cell reports methods, 1(3), . https://doi.org/10.1016/j.crmeth.2021.100015
Whiteaker, Jeffrey R, et al. "Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling." Cell reports methods vol. 1,3 (2021). doi: https://doi.org/10.1016/j.crmeth.2021.100015
Whiteaker JR, Sharma K, Hoffman MA, Kuhn E, Zhao L, Cocco AR, Schoenherr RM, Kennedy JJ, Voytovich U, Lin C, Fang B, Bowers K, Whiteley G, Colantonio S, Bocik W, Roberts R, Hiltke T, Boja E, Rodriguez H, McCormick F, Holderfield M, Carr SA, Koomen JM, Paulovich AG. Targeted mass spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP Kinase, and AKT signaling. Cell Rep Methods. 2021 Jul 26;1(3). doi: 10.1016/j.crmeth.2021.100015. Epub 2021 Jun 14. PMID: 34671754; PMCID: PMC8525888.
Copy Download .nbib Format: NLM
A highly annotated database of genes associated with platinum resistance in cancer.

Oncogene

Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG.
PMID: 34645978
Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13.

Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand...

Cite
Huang D, Savage SR, Calinawan AP, et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40(46):6395-6405doi: 10.1038/s41388-021-02055-2.
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021). A highly annotated database of genes associated with platinum resistance in cancer. Oncogene, 40(46), 6395-6405. https://doi.org/10.1038/s41388-021-02055-2
Huang, Dongqing, et al. "A highly annotated database of genes associated with platinum resistance in cancer." Oncogene vol. 40,46 (2021): 6395-6405. doi: https://doi.org/10.1038/s41388-021-02055-2
Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13. PMID: 34645978; PMCID: PMC8602037.
Copy Download .nbib Format: NLM
Proteogenomic characterization of pancreatic ductal adenocarcinoma.

Cell

Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, Krug K, Clark DJ, Schnaubelt M, Chen L, da Veiga Leprevost F, Eguez RV, Yang W, Pan J, Wen B, Dou Y, Jiang W, Liao Y, Shi Z, Terekhanova NV, Cao S, Lu RJ, Li Y, Liu R, Zhu H, Ronning P, Wu Y, Wyczalkowski MA, Easwaran H, Danilova L, Mer AS, Yoo S, Wang JM, Liu W, Haibe-Kains B, Thiagarajan M, Jewell SD, Hostetter G, Newton CJ, Li QK, Roehrl MH, Fenyö D, Wang P, Nesvizhskii AI, Mani DR, Omenn GS, Boja ES, Mesri M, Robles AI, Rodriguez H, Bathe OF, Chan DW, Hruban RH, Ding L, Zhang B, Zhang H.
PMID: 34534465
Cell. 2021 Sep 16;184(19):5031-5052.e26. doi: 10.1016/j.cell.2021.08.023.

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal...

Cite
Cao L, Huang C, Cui Zhou D, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184(19):5031-5052.e26doi: 10.1016/j.cell.2021.08.023.
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., da Veiga Leprevost, F., Eguez, R. V., Yang, W., Pan, J., Wen, B., Dou, Y., Jiang, W., Liao, Y., Shi, Z., Terekhanova, N. V., Cao, S., Lu, R. J., Li, Y., Liu, R., Zhu, H., Ronning, P., Wu, Y., Wyczalkowski, M. A., Easwaran, H., Danilova, L., Mer, A. S., Yoo, S., Wang, J. M., Liu, W., Haibe-Kains, B., Thiagarajan, M., Jewell, S. D., Hostetter, G., Newton, C. J., Li, Q. K., Roehrl, M. H., Fenyö, D., Wang, P., Nesvizhskii, A. I., Mani, D. R., Omenn, G. S., Boja, E. S., Mesri, M., Robles, A. I., Rodriguez, H., Bathe, O. F., Chan, D. W., Hruban, R. H., Ding, L., Zhang, B., Zhang, H. (2021). Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell, 184(19), 5031-5052.e26. https://doi.org/10.1016/j.cell.2021.08.023
Cao, Liwei, et al. "Proteogenomic characterization of pancreatic ductal adenocarcinoma." Cell vol. 184,19 (2021): 5031-5052.e26. doi: https://doi.org/10.1016/j.cell.2021.08.023
Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, Krug K, Clark DJ, Schnaubelt M, Chen L, da Veiga Leprevost F, Eguez RV, Yang W, Pan J, Wen B, Dou Y, Jiang W, Liao Y, Shi Z, Terekhanova NV, Cao S, Lu RJ, Li Y, Liu R, Zhu H, Ronning P, Wu Y, Wyczalkowski MA, Easwaran H, Danilova L, Mer AS, Yoo S, Wang JM, Liu W, Haibe-Kains B, Thiagarajan M, Jewell SD, Hostetter G, Newton CJ, Li QK, Roehrl MH, Fenyö D, Wang P, Nesvizhskii AI, Mani DR, Omenn GS, Boja ES, Mesri M, Robles AI, Rodriguez H, Bathe OF, Chan DW, Hruban RH, Ding L, Zhang B, Zhang H. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021 Sep 16;184(19):5031-5052.e26. doi: 10.1016/j.cell.2021.08.023. PMID: 34534465; PMCID: PMC8654574.
Copy Download .nbib Format: NLM
A highly annotated database of genes associated with platinum resistance in cancer.

Oncogene

Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG.
PMID: 34645978
Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13.

Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand...

Cite
Huang D, Savage SR, Calinawan AP, et al. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021;40(46):6395-6405doi: 10.1038/s41388-021-02055-2.
Huang, D., Savage, S. R., Calinawan, A. P., Lin, C., Zhang, B., Wang, P., Starr, T. K., Birrer, M. J., & Paulovich, A. G. (2021). A highly annotated database of genes associated with platinum resistance in cancer. Oncogene, 40(46), 6395-6405. https://doi.org/10.1038/s41388-021-02055-2
Huang, Dongqing, et al. "A highly annotated database of genes associated with platinum resistance in cancer." Oncogene vol. 40,46 (2021): 6395-6405. doi: https://doi.org/10.1038/s41388-021-02055-2
Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 Nov;40(46):6395-6405. doi: 10.1038/s41388-021-02055-2. Epub 2021 Oct 13. PMID: 34645978; PMCID: PMC8602037.
Copy Download .nbib Format: NLM
A proteogenomic portrait of lung squamous cell carcinoma.

Cell

Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA.
PMID: 34358469
Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016.

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications. We identify NSD3 as an...

Cite
Satpathy S, Krug K, Jean Beltran PM, et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021;184(16):4348-4371.e40doi: 10.1016/j.cell.2021.07.016.
Satpathy, S., Krug, K., Jean Beltran, P. M., Savage, S. R., Petralia, F., Kumar-Sinha, C., Dou, Y., Reva, B., Kane, M. H., Avanessian, S. C., Vasaikar, S. V., Krek, A., Lei, J. T., Jaehnig, E. J., Omelchenko, T., Geffen, Y., Bergstrom, E. J., Stathias, V., Christianson, K. E., Heiman, D. I., Cieslik, M. P., Cao, S., Song, X., Ji, J., Liu, W., Li, K., Wen, B., Li, Y., Gümüş, Z. H., Selvan, M. E., Soundararajan, R., Visal, T. H., Raso, M. G., Parra, E. R., Babur, �. �., Vats, P., Anand, S., Schraink, T., Cornwell, M., Rodrigues, F. M., Zhu, H., Mo, C. K., Zhang, Y., da Veiga Leprevost, F., Huang, C., Chinnaiyan, A. M., Wyczalkowski, M. A., Omenn, G. S., Newton, C. J., Schurer, S., Ruggles, K. V., Fenyö, D., Jewell, S. D., Thiagarajan, M., Mesri, M., Rodriguez, H., Mani, S. A., Udeshi, N. D., Getz, G., Suh, J., Li, Q. K., Hostetter, G., Paik, P. K., Dhanasekaran, S. M., Govindan, R., Ding, L., Robles, A. I., Clauser, K. R., Nesvizhskii, A. I., Wang, P., Carr, S. A., Zhang, B., Mani, D. R., Gillette, M. A. (2021). A proteogenomic portrait of lung squamous cell carcinoma. Cell, 184(16), 4348-4371.e40. https://doi.org/10.1016/j.cell.2021.07.016
Satpathy, Shankha, et al. "A proteogenomic portrait of lung squamous cell carcinoma." Cell vol. 184,16 (2021): 4348-4371.e40. doi: https://doi.org/10.1016/j.cell.2021.07.016
Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016. PMID: 34358469; PMCID: PMC8475722.
Copy Download .nbib Format: NLM
Proteogenomic characterization of pancreatic ductal adenocarcinoma.

Cell

Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, Krug K, Clark DJ, Schnaubelt M, Chen L, da Veiga Leprevost F, Eguez RV, Yang W, Pan J, Wen B, Dou Y, Jiang W, Liao Y, Shi Z, Terekhanova NV, Cao S, Lu RJ, Li Y, Liu R, Zhu H, Ronning P, Wu Y, Wyczalkowski MA, Easwaran H, Danilova L, Mer AS, Yoo S, Wang JM, Liu W, Haibe-Kains B, Thiagarajan M, Jewell SD, Hostetter G, Newton CJ, Li QK, Roehrl MH, Fenyö D, Wang P, Nesvizhskii AI, Mani DR, Omenn GS, Boja ES, Mesri M, Robles AI, Rodriguez H, Bathe OF, Chan DW, Hruban RH, Ding L, Zhang B, Zhang H.
PMID: 34534465
Cell. 2021 Sep 16;184(19):5031-5052.e26. doi: 10.1016/j.cell.2021.08.023.

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient survival. Toward understanding the underlying molecular alterations that drive PDAC oncogenesis, we conducted comprehensive proteogenomic analysis of 140 pancreatic cancers, 67 normal adjacent tissues, and 9 normal...

Cite
Cao L, Huang C, Cui Zhou D, et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021;184(19):5031-5052.e26doi: 10.1016/j.cell.2021.08.023.
Cao, L., Huang, C., Cui Zhou, D., Hu, Y., Lih, T. M., Savage, S. R., Krug, K., Clark, D. J., Schnaubelt, M., Chen, L., da Veiga Leprevost, F., Eguez, R. V., Yang, W., Pan, J., Wen, B., Dou, Y., Jiang, W., Liao, Y., Shi, Z., Terekhanova, N. V., Cao, S., Lu, R. J., Li, Y., Liu, R., Zhu, H., Ronning, P., Wu, Y., Wyczalkowski, M. A., Easwaran, H., Danilova, L., Mer, A. S., Yoo, S., Wang, J. M., Liu, W., Haibe-Kains, B., Thiagarajan, M., Jewell, S. D., Hostetter, G., Newton, C. J., Li, Q. K., Roehrl, M. H., Fenyö, D., Wang, P., Nesvizhskii, A. I., Mani, D. R., Omenn, G. S., Boja, E. S., Mesri, M., Robles, A. I., Rodriguez, H., Bathe, O. F., Chan, D. W., Hruban, R. H., Ding, L., Zhang, B., Zhang, H. (2021). Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell, 184(19), 5031-5052.e26. https://doi.org/10.1016/j.cell.2021.08.023
Cao, Liwei, et al. "Proteogenomic characterization of pancreatic ductal adenocarcinoma." Cell vol. 184,19 (2021): 5031-5052.e26. doi: https://doi.org/10.1016/j.cell.2021.08.023
Cao L, Huang C, Cui Zhou D, Hu Y, Lih TM, Savage SR, Krug K, Clark DJ, Schnaubelt M, Chen L, da Veiga Leprevost F, Eguez RV, Yang W, Pan J, Wen B, Dou Y, Jiang W, Liao Y, Shi Z, Terekhanova NV, Cao S, Lu RJ, Li Y, Liu R, Zhu H, Ronning P, Wu Y, Wyczalkowski MA, Easwaran H, Danilova L, Mer AS, Yoo S, Wang JM, Liu W, Haibe-Kains B, Thiagarajan M, Jewell SD, Hostetter G, Newton CJ, Li QK, Roehrl MH, Fenyö D, Wang P, Nesvizhskii AI, Mani DR, Omenn GS, Boja ES, Mesri M, Robles AI, Rodriguez H, Bathe OF, Chan DW, Hruban RH, Ding L, Zhang B, Zhang H. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell. 2021 Sep 16;184(19):5031-5052.e26. doi: 10.1016/j.cell.2021.08.023. PMID: 34534465; PMCID: PMC8654574.
Copy Download .nbib Format: NLM
A proteogenomic portrait of lung squamous cell carcinoma.

Cell

Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA.
PMID: 34358469
Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016.

Lung squamous cell carcinoma (LSCC) remains a leading cause of cancer death with few therapeutic options. We characterized the proteogenomic landscape of LSCC, providing a deeper exposition of LSCC biology with potential therapeutic implications. We identify NSD3 as an...

Cite
Satpathy S, Krug K, Jean Beltran PM, et al. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021;184(16):4348-4371.e40doi: 10.1016/j.cell.2021.07.016.
Satpathy, S., Krug, K., Jean Beltran, P. M., Savage, S. R., Petralia, F., Kumar-Sinha, C., Dou, Y., Reva, B., Kane, M. H., Avanessian, S. C., Vasaikar, S. V., Krek, A., Lei, J. T., Jaehnig, E. J., Omelchenko, T., Geffen, Y., Bergstrom, E. J., Stathias, V., Christianson, K. E., Heiman, D. I., Cieslik, M. P., Cao, S., Song, X., Ji, J., Liu, W., Li, K., Wen, B., Li, Y., Gümüş, Z. H., Selvan, M. E., Soundararajan, R., Visal, T. H., Raso, M. G., Parra, E. R., Babur, �. �., Vats, P., Anand, S., Schraink, T., Cornwell, M., Rodrigues, F. M., Zhu, H., Mo, C. K., Zhang, Y., da Veiga Leprevost, F., Huang, C., Chinnaiyan, A. M., Wyczalkowski, M. A., Omenn, G. S., Newton, C. J., Schurer, S., Ruggles, K. V., Fenyö, D., Jewell, S. D., Thiagarajan, M., Mesri, M., Rodriguez, H., Mani, S. A., Udeshi, N. D., Getz, G., Suh, J., Li, Q. K., Hostetter, G., Paik, P. K., Dhanasekaran, S. M., Govindan, R., Ding, L., Robles, A. I., Clauser, K. R., Nesvizhskii, A. I., Wang, P., Carr, S. A., Zhang, B., Mani, D. R., Gillette, M. A. (2021). A proteogenomic portrait of lung squamous cell carcinoma. Cell, 184(16), 4348-4371.e40. https://doi.org/10.1016/j.cell.2021.07.016
Satpathy, Shankha, et al. "A proteogenomic portrait of lung squamous cell carcinoma." Cell vol. 184,16 (2021): 4348-4371.e40. doi: https://doi.org/10.1016/j.cell.2021.07.016
Satpathy S, Krug K, Jean Beltran PM, Savage SR, Petralia F, Kumar-Sinha C, Dou Y, Reva B, Kane MH, Avanessian SC, Vasaikar SV, Krek A, Lei JT, Jaehnig EJ, Omelchenko T, Geffen Y, Bergstrom EJ, Stathias V, Christianson KE, Heiman DI, Cieslik MP, Cao S, Song X, Ji J, Liu W, Li K, Wen B, Li Y, Gümüş ZH, Selvan ME, Soundararajan R, Visal TH, Raso MG, Parra ER, Babur Ö, Vats P, Anand S, Schraink T, Cornwell M, Rodrigues FM, Zhu H, Mo CK, Zhang Y, da Veiga Leprevost F, Huang C, Chinnaiyan AM, Wyczalkowski MA, Omenn GS, Newton CJ, Schurer S, Ruggles KV, Fenyö D, Jewell SD, Thiagarajan M, Mesri M, Rodriguez H, Mani SA, Udeshi ND, Getz G, Suh J, Li QK, Hostetter G, Paik PK, Dhanasekaran SM, Govindan R, Ding L, Robles AI, Clauser KR, Nesvizhskii AI, Wang P, Carr SA, Zhang B, Mani DR, Gillette MA. A proteogenomic portrait of lung squamous cell carcinoma. Cell. 2021 Aug 05;184(16):4348-4371.e40. doi: 10.1016/j.cell.2021.07.016. PMID: 34358469; PMCID: PMC8475722.
Copy Download .nbib Format: NLM
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function.

Science signaling

Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR.
PMID: 34429382
Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606.

Chimeric antigen receptor (CAR)-modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T...

Cite
Salter AI, Rajan A, Kennedy JJ, et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021;14(697)doi: 10.1126/scisignal.abe2606.
Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., & Riddell, S. R. (2021). Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Science signaling, 14(697), . https://doi.org/10.1126/scisignal.abe2606
Salter, Alexander I, et al. "Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function." Science signaling vol. 14,697 (2021). doi: https://doi.org/10.1126/scisignal.abe2606
Salter AI, Rajan A, Kennedy JJ, Ivey RG, Shelby SA, Leung I, Templeton ML, Muhunthan V, Voillet V, Sommermeyer D, Whiteaker JR, Gottardo R, Veatch SL, Paulovich AG, Riddell SR. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci Signal. 2021 Aug 24;14(697). doi: 10.1126/scisignal.abe2606. PMID: 34429382; PMCID: PMC8613804.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries